Evidence map›Paper›PMID 42448976›Full record

ArticleAnnals of surgical oncology2026

Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.

Jun Yoshino, Hakon Blomstrand, Sebastian Fjellander, Johan Svensson, Asif Halimi, Ella Kesti, Hanna Seppänen, Caroline Vilhav, Daniel Öhlund, Caj Haglund and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jun YoshinoDepartment of Diagnostics and Intervention, Surgery, Umeå University, Umeå, Sweden.
Hakon BlomstrandDepartment of Clinical Pathology, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Sebastian FjellanderDepartment of Clinical Pathology, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Johan SvenssonDepartment of Statistics, Umeå School of Business Economics and Statistics, Umeå University, Umeå, Sweden.
Asif HalimiDepartment of Diagnostics and Intervention, Surgery, Umeå University, Umeå, Sweden.
Ella KestiDepartment of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Hanna SeppänenDepartment of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Caroline VilhavDepartment of Transplantation Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
Daniel ÖhlundDepartment of Diagnostics and Intervention, Oncology, and Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden.
Caj HaglundDepartment of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Nils O ElanderDepartment of Oncology, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Peter NarediDepartment of Transplantation Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
Malin SundDepartment of Diagnostics and Intervention, Surgery, Umeå University, Umeå, Sweden.
Oskar FranklinDepartment of Diagnostics and Intervention, Surgery, Umeå University, Umeå, Sweden. oskar.franklin@umu.se.ORCID http://orcid.org/0000-0002-3777-6887

Funding

Bengt Ihre Foundation SLS-885861Bengt Ihre Foundation SLS-960529Bengt Ihre Foundation SLS-986656Cancerforskningfonden i Norrland AMP 24-1154FORSS FORSS-1013610Lennart Glans Stiftelse 990326Lion's Research Fund, Linköping and Region Östergötland RÖ-1006094Lion's Research Fund, Linköping and Region Östergötland RÖ-1023270Region Västerbotten RV-970069Region Västerbotten RV-979958Region Västerbotten RV-982481Region Västerbotten RV-995863Scandinavia-Japan Sasakawa Foundation GA24-JPN-0150Sjöbergstiftelsen LP 23-2337
6 · The paper itself

Abstract

backgroundTargeting Claudin-18 isoform 2 (CLDN18.2) improves survival in CLDN18.2 positive advanced gastric cancer and similar trials on metastatic pancreatic ductal adenocarcinoma (PDAC) are ongoing. Here, we aimed to assess the prevalence of CLDN18.2 positivity in resected PDAC including its association with overall survival (OS).

methodsImmunohistochemical analysis on paraffin-embedded primary tumors and lymph node metastases was performed from patients who underwent curative-intent PDAC resection at four centers in Sweden and Finland. In addition, survival outcomes were assessed.

resultsIn total, 599 primary tumors and 197 lymph nodes were analyzed. CLDN18.2 positivity was observed in 138 of 599 of primary tumors (23%) and 35 of 197 metastatic lymph nodes (17.8%). CLDN18.2 positivity in primary tumors was associated with higher tumor grade (p = 0.016). Median OS was longer in patients with CLDN18.2-positive tumors (27.7 vs. 21.1 months). Adjusted analysis identified CLDN18.2 positivity as an independent prognostic variable for OS (hazard ratio 0.79; 95% confidence interval 0.64-0.98).

conclusionsCLDN18.2 is expressed in 23% of primary PDAC tumours, indicating its potential to be used as a therapeutic target in a significant proportion of PDAC patients, and its expression is associated with improved OS in resected PDAC, supporting its role as a prognostic marker.

Indexed as

AdenocarcinomaBiomarkers, TumorCarcinoma, Pancreatic DuctalClaudinsPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm StagingBiomarkers, TumorClaudinsCLDN18 protein, humanCLDN18.2ImmunohistochemistryPancreatic ductal adenocarcinomaPrognosisSurgical resection

Identifiers

PMID42448976
PMCPMC13585933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.